Drug Profile
Research programme: oxalate degrading enzymes - Arranta Bio
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Captozyme
- Class Enzymes
- Mechanism of Action Oxalate inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Primary hyperoxaluria
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Primary-hyperoxaluria in USA
- 14 Aug 2016 Early research in Primary hyperoxaluria in USA (unspecified route)